I am supportive of doing something. I am actually not against this bill, but I think it's a piecemeal approach.

Yesterday, I reintroduced the Affordable Prescriptions for Patients through Competition Act together with Subcommittee Ranking Member Buck and Senators Cornyn and Blumenthal.

Absolutely, Mr. Buck, and I look forward to our ongoing discussion on that really critical issue.

In closing, the American people deserve a government that is in their corner fighting for them to take on drug profiteering and other barriers to affordable healthcare.

We also need to enhance and improve the laws with regard to our power of enforcement.

thank you for your testimony that I think really helped to inform the work of this Committee

It is unacceptable that people suffering from diabetes must worry about life-threatening consequences of not being able to afford insulin.

It is unacceptable that many seniors cannot afford the arthritis medication they need to perform everyday tasks.

Break them up. That is the remedy that I have advocated on some of the Big Tech companies.

to explicitly prohibit healthcare mergers that enable greater exploitation of existing market power and are likely to result in harm to consumers.

It would eliminate the abuses of product hopping.

This legislation addresses product hopping, a particular abusive form of conduct used by drug manufacturers to extend their monopolies.

I want to thank Senators Grassley, Cornyn, and Klobuchar, and Blumenthal for their work on these important issues.

I think these are good initiatives. They're really a top-down, not bottom-up approach.

It is unacceptable that hundreds of thousands of cancer patients are reportedly delaying lifesaving care.

I look forward to joining Mr. Issa in reforming our Nation's patent laws.

I think that regulatory reform and competition advocacy are very, very important.

I am also pleased to be in partnership with Representatives Johnson and Issa in a House companion to a bill.